High-Risk Prostate Cancer is Worth Further Risk Stratification

European Urology

Volumn 53, Issue 5, 2008, Pages 872-873

  Maffezzini, Massimo ^a  

^a GALLIERA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; EDITORIAL; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT;

EUROPE; HUMANS; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SURVIVAL RATE; TIME FACTORS;

EID: 41149121215     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.10.046     Document Type: Editorial

References (5)

1. Yossepowitch O., Eggener S.E., Serio A.M., et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol 53 (2008) 950-959
2. Swanson G., Thompson I., Basler J., and Crawford E.D. Metastatic prostate cancer: does treatment of the primary tumor matter?. J Urol 176 (2006) 1292-1298
3. Maffezzini M., Bossi A., and Collette L. Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer. Eur Urol 51 (2007) 605-613
4. Thompson I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiation therapy for pathologically advanced prostate cancer: a randomised clinical trial. JAMA 296 (2006) 2329-2335
5. Northouse L.L., Mood D.W., Montie J.E., et al. Living with prostate cancer: patients' and spouses' psychosocial status and quality of life. J Clin Oncol 25 (2007) 4171-4177